→ Tim Coleman has retired as chief technology officer at Eli Lilly, ending a 35-year career with the pharma giant in his hometown of Indianapolis. Coleman held countless positions at Lilly before his appointment as …
Amgen seeks to buoy Tepezza with injectable data in face of incoming competition
Amgen said that an injectable version of its eye drug Tepezza succeeded in a Phase 3 study for thyroid eye disease, setting up a showdown


